Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
Veracyte, Inc. furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1.
The company states this information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference unless specifically so stated.
Veracyte, Inc. (VCYT) officer Jonathan Wygant, VP and Chief Accounting Officer, reported an equity award on Form 4. On 10/28/2025, he acquired 2,886 shares of common stock at $0 under transaction code A, reflecting a restricted stock unit grant. Following the transaction, his beneficial ownership stands at 49,665 shares, held directly.
The filing notes the RSUs were awarded on October 28, 2025 and vest in full on the first anniversary of the grant date, subject to his continued employment.
Veracyte, Inc. insider Phillip G. Febbo sold 8,349 shares of common stock on 10/06/2025 at a weighted average price of $36.0174, reducing his beneficial ownership to 92,441 shares. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on 09/04/2024, and individual sale prices ranged from $35.82 to $36.28. The Form 4 was signed by an attorney-in-fact on 10/07/2025. No options or derivative transactions were reported.
Veracyte, Inc. notice reports a proposed sale of 8,349 common shares on NASDAQ with an aggregate market value of $300,564. The shares represent restricted stock units acquired from the issuer on 12/02/2024 and were paid/issued on the same date. The filing states there were 78,671,588 shares outstanding, and the seller reports no securities sold in the prior three months. The sale is planned for 10/06/2025. The filer affirms they are not aware of undisclosed material adverse information and signs the notice consistent with Rule 144 requirements.
Veracyte (VCYT) insider transaction: The company’s Chief Commercial Officer-CLIA reported a sale of 2,539 shares of common stock at $35 on 10/01/2025, coded “S”. The filing notes the trades were made under a Rule 10b5-1 plan adopted on June 9, 2025. Following the transaction, the reporting person beneficially owns 89,099 shares, held directly.
Robert S. Epstein, a director of Veracyte, Inc. (VCYT), reported transactions on a Form 4 dated 10/01/2025. He exercised 10,000 stock options with an exercise price of $7.94, resulting in 10,000 shares issued, and subsequently sold 21,473 common shares at a weighted average sale price of $35.0768 (individual sales ranged $35.00–$35.30). The Form shows his beneficial ownership changing from 83,919 shares after the option exercise to 62,446 shares following the sale. The transactions were made under a Rule 10b5-1 plan adopted June 5, 2025, and the Form was signed by an attorney-in-fact on 10/03/2025.
An officer of Veracyte, Inc. executed a programmed sale of 2,160 shares of the company's common stock on 10/01/2025 under a Rule 10b5-1 trading plan. The sale's weighted average price was approximately $35.00 per share (individual prices ranged $35.00–$35.05), and the reporting person retained beneficial ownership of 89,439 shares after the transactions. The filer notes the sales were made pursuant to a plan adopted on 9/04/2024, and that detailed per-price share counts are available on request.
Veracyte, Inc. filed a Form 144 reporting a proposed sale of 2,539 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 10/01/2025. The filing lists an aggregate market value of $87,163.87 based on 78,671,588 shares outstanding. The shares were acquired on 03/02/2024 as restricted stock units issued by the company and were paid on that same date. The filer reports no securities sold in the past three months and certifies they have no undisclosed material adverse information regarding the issuer.
Veracyte (VCYT) reports a proposed sale of 2,160 common shares, representing restricted stock units acquired on 03/02/2025, with an aggregate market value of $74,152.80. The shares are to be sold through Morgan Stanley Smith Barney LLC on or about 10/01/2025 on the NASDAQ. The issuer's outstanding shares are listed as 78,671,588, so the proposed sale equals approximately 0.0027% of outstanding shares. The filing also discloses prior 10b5-1 sales by the same account of 2,283 shares on 09/19/2025 for gross proceeds of $76,919.50. The securities were acquired as Restricted Stock Units from the issuer and no cash payment was required at acquisition.
Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported the sale of 2,283 shares of Veracyte common stock on 09/19/2025 under a pre-established Rule 10b5-1 plan adopted on 09/04/2024. The filing shows a weighted-average sale price of $33.6923 per share, with individual sale prices ranging from $33.50 to $34.00. After the transaction, Ms. McGuire beneficially owned 91,599 shares, reported as direct ownership.
The Form 4 was executed by an attorney-in-fact and explicitly states the sale was made pursuant to the 10b5-1 plan; additional per-price share breakdowns are available on request to the SEC, the issuer, or a shareholder.
Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported the sale of 2,283 shares of Veracyte common stock on 09/19/2025 under a pre-established Rule 10b5-1 plan adopted on 09/04/2024. The filing shows a weighted-average sale price of $33.6923 per share, with individual sale prices ranging from $33.50 to $34.00. After the transaction, Ms. McGuire beneficially owned 91,599 shares, reported as direct ownership.
The Form 4 was executed by an attorney-in-fact and explicitly states the sale was made pursuant to the 10b5-1 plan; additional per-price share breakdowns are available on request to the SEC, the issuer, or a shareholder.